RESUMEN
Anxiety commonly co-occurs with obsessive-compulsive disorder (OCD). Both of them are closely related to stress. However, the shared neurobiological substrates and therapeutic targets remain unclear. Here we report an amelioration of both anxiety and OCD via the histamine presynaptic H3 heteroreceptor on glutamatergic afferent terminals from the prelimbic prefrontal cortex (PrL) to the nucleus accumbens (NAc) core, a vital node in the limbic loop. The NAc core receives direct hypothalamic histaminergic projections, and optogenetic activation of hypothalamic NAc core histaminergic afferents selectively suppresses glutamatergic rather than GABAergic synaptic transmission in the NAc core via the H3 receptor and thus produces an anxiolytic effect and improves anxiety- and obsessive-compulsive-like behaviors induced by restraint stress. Although the H3 receptor is expressed in glutamatergic afferent terminals from the PrL, basolateral amygdala (BLA), and ventral hippocampus (vHipp), rather than the thalamus, only the PrL- and not BLA- and vHipp-NAc core glutamatergic pathways among the glutamatergic afferent inputs to the NAc core is responsible for co-occurrence of anxiety- and obsessive-compulsive-like behaviors. Furthermore, activation of the H3 receptor ameliorates anxiety and obsessive-compulsive-like behaviors induced by optogenetic excitation of the PrL-NAc glutamatergic afferents. These results demonstrate a common mechanism regulating anxiety- and obsessive-compulsive-like behaviors and provide insight into the clinical treatment strategy for OCD with comorbid anxiety by targeting the histamine H3 receptor in the NAc core.
Asunto(s)
Trastornos de Ansiedad/tratamiento farmacológico , Agonistas de los Receptores Histamínicos/administración & dosificación , Núcleo Accumbens/fisiopatología , Trastorno Obsesivo Compulsivo/tratamiento farmacológico , Receptores Histamínicos H3/metabolismo , Vías Aferentes/efectos de los fármacos , Vías Aferentes/fisiopatología , Animales , Trastornos de Ansiedad/etiología , Trastornos de Ansiedad/fisiopatología , Trastornos de Ansiedad/psicología , Modelos Animales de Enfermedad , Glutamatos/metabolismo , Histamina/metabolismo , Antagonistas de los Receptores Histamínicos H3/administración & dosificación , Humanos , Área Hipotalámica Lateral/efectos de los fármacos , Área Hipotalámica Lateral/fisiopatología , Masculino , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Núcleo Accumbens/citología , Núcleo Accumbens/efectos de los fármacos , Trastorno Obsesivo Compulsivo/etiología , Trastorno Obsesivo Compulsivo/fisiopatología , Trastorno Obsesivo Compulsivo/psicología , Optogenética , Técnicas de Placa-Clamp , Corteza Prefrontal/citología , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/fisiopatología , Terminales Presinápticos/efectos de los fármacos , Terminales Presinápticos/metabolismo , Ratas , Ratas Transgénicas , Técnicas Estereotáxicas , Estrés Psicológico/complicaciones , Estrés Psicológico/psicología , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiologíaRESUMEN
Unmyelinated tactile (C-tactile or CT) afferents are abundant in arm hairy skin and have been suggested to signal features of social affective touch. Here, we recorded from unmyelinated low-threshold mechanosensitive afferents in the peroneal and radial nerves. The most distal receptive fields were located on the proximal phalanx of the third finger for the superficial branch of the radial nerve and near the lateral malleolus for the peroneal nerve. We found that the physiological properties with regard to conduction velocity and mechanical threshold, as well as their tuning to brush velocity, were similar in CT units across the antebrachial (n = 27), radial (n = 8), and peroneal (n = 4) nerves. Moreover, we found that although CT afferents are readily found during microneurography of the arm nerves, they appear to be much more sparse in the lower leg compared with C-nociceptors. We continued to explore CT afferents with regard to their chemical sensitivity and found that they could not be activated by topical application to their receptive field of either the cooling agent menthol or the pruritogen histamine. In light of previous studies showing the combined effects that temperature and mechanical stimuli have on these neurons, these findings add to the growing body of research suggesting that CT afferents constitute a unique class of sensory afferents with highly specialized mechanisms for transducing gentle touch.NEW & NOTEWORHY Unmyelinated tactile (CT) afferents are abundant in arm hairy skin and are thought to signal features of social affective touch. We show that CTs are also present but are relatively sparse in the lower leg compared with C-nociceptors. CTs display similar physiological properties across the arm and leg nerves. Furthermore, CT afferents do not respond to the cooling agent menthol or the pruritogen histamine, and their mechanical response properties are not altered by these chemicals.
Asunto(s)
Afecto , Antipruriginosos/farmacología , Agonistas de los Receptores Histamínicos/farmacología , Mecanorreceptores/fisiología , Mentol/farmacología , Fibras Nerviosas Amielínicas/fisiología , Nervio Peroneo/fisiología , Percepción del Tacto/fisiología , Adulto , Vías Aferentes/efectos de los fármacos , Vías Aferentes/fisiología , Antipruriginosos/administración & dosificación , Femenino , Histamina/farmacología , Agonistas de los Receptores Histamínicos/administración & dosificación , Humanos , Pierna/inervación , Masculino , Mecanorreceptores/efectos de los fármacos , Mentol/administración & dosificación , Fibras Nerviosas Amielínicas/efectos de los fármacos , Nociceptores/efectos de los fármacos , Nociceptores/fisiología , Nervio Peroneo/efectos de los fármacos , Nervio Radial/efectos de los fármacos , Nervio Radial/fisiología , Percepción del Tacto/efectos de los fármacos , Adulto JovenRESUMEN
Context: IL-33 is a pro-inflammatory cytokine that is involved in the development of chronic inflammatory diseases and the initiation of allergic inflammation in response to pathogens and acts an alarmin.Objective: Present study aims to explore the IL-33 mediated effects of histamine induced allergic inflammation in human mast cells.Materials and methods: In this study, cord blood derived CD34+ mast cells and HMC-1 cells were primed with IL-33 followed by the stimulation with histamine. We investigated the functional activation of mast cell by intracellular calcium release using calcium mobilization assay, release of granular content using degranulation assay, profiling of various inflammatory and regulatory cytokines as well as chemokines by Luminex Bioplex assay and its signaling mechanisms involved using western blot analysis.Results: In our study, we found that the IL-33 acts as a mediator in the allergic inflammation induced by the histamine. IL-33 potentiates the release of intracellular calcium and degranulation content in human mast cells. Also, it enhances the production of Th2, Th1 cytokines and chemokines and down-regulates the production of regulatory cytokine. Furthermore, it enhanced the phosphorylation of the signaling molecules such as ERK, Akt, and NFκB in activated mast cells. Therefore, IL-33 acts as a potent activator of mast cells and it can elicit inflammatory response synergistically with histamine.Conclusions: Taken together, IL-33 acts as a potent mediator by inducing the inflammatory response in activated mast cells, hence increasing their responsiveness to antigens and amplifying the allergic response.
Asunto(s)
Hipersensibilidad/inmunología , Inflamación/inmunología , Interleucina-33/metabolismo , Mastocitos/inmunología , Células Cultivadas , Citocinas/metabolismo , Histamina/administración & dosificación , Agonistas de los Receptores Histamínicos/administración & dosificación , Humanos , Hipersensibilidad/etiología , Hipersensibilidad/metabolismo , Hipersensibilidad/patología , Inflamación/inducido químicamente , Inflamación/metabolismo , Inflamación/patología , Interleucina-33/genética , Mastocitos/efectos de los fármacos , Mastocitos/metabolismo , Mastocitos/patología , FN-kappa B/metabolismo , Transducción de SeñalRESUMEN
Vertigo is associated with a wide range of vestibular pathologies. It increasingly affects the elderly, with a high cost to society. Solutions include vestibular suppressants and vestibular rehabilitation, which form the mainstay of therapy. Antihistamines represent the largest class of agents used to combat vestibular vertigo symptoms. Agents targeting the H1 and H3 receptors have been in clinical use for several decades as single agents. Nonetheless, effective management of vertigo proves elusive as many treatments largely address only associated symptoms, and with questionable efficacy. Additionally, the primary and limiting side effect of sedation is counterproductive to normal functioning and the natural recovery process occurring via central compensation. To address these issues, the timing of administration of betahistine, the mainstay H3 antihistamine, can be fine-tuned, while bioavailability is also being improved. Other approaches include antihistamine combination studies, devices, physical therapy and behavioural interventions. Recently demonstrated expression of H4 receptors in the peripheral vestibular system represents a new potential drug target for treating vestibular disorders. A number of novel selective H4 antagonists are active in vestibular models in vivo. The preclinical potential of SENS-111 (Seliforant), an oral first-in-class selective H4 antagonist is the only such molecule to date to be translated into the clinical setting. With an excellent safety profile and notable absence of sedation, encouraging outcomes in an induced vertigo model in healthy volunteers have led to ongoing clinical studies in acute unilateral vestibulopathy, with the hope that H4 antagonists will offer new effective therapeutic options to patients suffering from vertigo.
Asunto(s)
Antagonistas de los Receptores Histamínicos/administración & dosificación , Receptores Histamínicos H4/antagonistas & inhibidores , Vértigo/tratamiento farmacológico , Anciano , Animales , Azetidinas/administración & dosificación , Azetidinas/efectos adversos , Azetidinas/farmacología , Betahistina/administración & dosificación , Betahistina/farmacología , Agonistas de los Receptores Histamínicos/administración & dosificación , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores Histamínicos/efectos adversos , Antagonistas de los Receptores Histamínicos/farmacología , Humanos , Pirimidinas/administración & dosificación , Pirimidinas/efectos adversos , Pirimidinas/farmacología , Receptores Histamínicos H4/metabolismo , Vértigo/fisiopatologíaAsunto(s)
Antipsicóticos/efectos adversos , Betahistina/administración & dosificación , Clozapina/efectos adversos , Aumento de Peso/efectos de los fármacos , Adulto , Antipsicóticos/administración & dosificación , Betahistina/farmacología , Clozapina/administración & dosificación , Femenino , Agonistas de los Receptores Histamínicos/administración & dosificación , Agonistas de los Receptores Histamínicos/farmacología , Humanos , Esquizofrenia/tratamiento farmacológicoRESUMEN
Patients with schizophrenia experience higher rates of obesity and related morbidity and mortality than the general population does. Given preclinical studies revealing the role of histamine H1 receptor in human eating behavior, and the potential of olanzapine to block with this system, we hypothesized that histamine H1 receptor agonists may be beneficial in reducing antipsychotic-associated weight gain. In the present study, 36 patients with a diagnosis of schizophrenia or schizoaffective disorder and treated with olanzapine were randomized to betahistine (48 mg/d) or matching placebo for 16 weeks. Study outcomes were change in body weight from baseline and effect on antipsychotic efficacy of olanzapine. The patients in the betahistine group had less weight gain (-1.95 kg) compared with placebo group (5.6 + 5.5 kg vs 6.9 + 5.6 kg, respectively). Positive and Negative Syndrome Scale Questionnaire showed improvement within each group and that subjects treated with betahistine enjoyed an improvement (reduction) by a mean of 35.7 points, higher when compared with placebo subjects who had a reduction of 26.6 points (P = 0.233). An almost equal amount of subjects in both groups experienced adverse effects during the course of this study (87.5% of betahistine vs 85.0% of placebo-treated subjects). Overall, there were no clinically marked differences in safety signals between both groups. A larger study addressing the weaknesses of this pilot study is warranted.
Asunto(s)
Antipsicóticos/administración & dosificación , Benzodiazepinas/administración & dosificación , Betahistina/administración & dosificación , Agonistas de los Receptores Histamínicos/administración & dosificación , Esquizofrenia/tratamiento farmacológico , Aumento de Peso/efectos de los fármacos , Adolescente , Adulto , Antipsicóticos/efectos adversos , Benzodiazepinas/efectos adversos , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Internacionalidad , Masculino , Olanzapina , Proyectos Piloto , Trastornos Psicóticos/diagnóstico , Trastornos Psicóticos/tratamiento farmacológico , Esquizofrenia/diagnóstico , Aumento de Peso/fisiología , Adulto JovenRESUMEN
BACKGROUND: The skin prick test (SPT) is a valid and approved tool that is used to diagnose atopic diseases. The SPT is accurate, safe, simple and inexpensive. However, the histamine concentration used as a positive control in the SPT varies among centers. OBJECTIVE: To compare SPT results using different concentrations of locally-prepared and imported histamine solutions. METHOD: This prospective, randomized, double-blind, self-controlled study was performed in healthy adult volunteers. The SPT was performed using 4 concentrations of histamine solutions (imported, 1 mg/mL; locally-prepared, 1, 5 and 10 mg/mL). Locally-prepared histamine positive controls were prepared from histamine biphosphate monohydrate using sterile technique. RESULTS: Seventy-five adult volunteers (mean age, 36 years) were included in the study. Eight volunteers were male and 9 had a history of atopy. Mean wheal diameter (MWD) for imported histamine was 3.49 mm for a concentration of 1 mg/mL, and that of locally-prepared histamine was 2.94 mm, 5.05 mm and 5.52 mm for concentrations of 1, 5 and 10 mg/mL histamine, respectively. Negative SPT results (MWD <3 mm) were found in 11 subjects (14.7%) who received imported histamine and 26 subjects (34.7%) who received the locally-prepared histamine at concentration of 1 mg/mL. All subjects tested with locally-prepared histamine at concentrations of 5 and 10 mg/mL had a MWD > 3 mm. CONCLUSIONS: Locally-prepared histamine base at concentrations of 5 and 10 mg/mL yielded better positive results than both imported and locally-prepared histamine at a concentration of 1 mg/mL.
Asunto(s)
Agonistas de los Receptores Histamínicos/administración & dosificación , Histamina/análogos & derivados , Hipersensibilidad Inmediata/diagnóstico , Pruebas Cutáneas/métodos , Adulto , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Histamina/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Estudios ProspectivosRESUMEN
NEW FINDINGS: What is the central question of this study? Is exercise-induced oxidative stress the upstream exercise-related signalling mechanism that leads to sustained postexercise vasodilatation via activation of H1 and H2 histamine receptors? What is the main finding and its importance? Systemic administration of the antioxidant ascorbate inhibits sustained postexercise vasodilatation to the same extent as seen previously with H1 and H2 histamine receptor blockade following small muscle-mass exercise. However, ascorbate has a unique ability to catalyse the degradation of histamine. We also found that systemic infusion of the antioxidant N-acetylcysteine had no effect on sustained postexercise vasodilatation, suggesting that exercise-induced oxidative stress does not contribute to sustained postexercise vasodilatation. An acute bout of aerobic exercise elicits a sustained postexercise vasodilatation that is mediated by histamine H1 and H2 receptor activation. However, the upstream signalling pathway that leads to postexercise histamine receptor activation is unknown. We tested the hypothesis that the potent antioxidant ascorbate would inhibit this histaminergic vasodilatation following exercise. Subjects performed 1 h of unilateral dynamic knee extension at 60% of peak power in three conditions: (i) control; (ii) i.v. ascorbate infusion; and (iii) ascorbate infusion plus oral H1 /H2 histamine receptor blockade. Femoral artery blood flow was measured (using Doppler ultrasound) before exercise and for 2 h postexercise. Femoral vascular conductance was calculated as flow/pressure. Postexercise vascular conductance was greater for control conditions (3.4 ± 0.1 ml min(-1) mmHg(-1) ) compared with ascorbate (2.7 ± 0.1 ml min(-1) mmHg(-1) ; P < 0.05) and ascorbate plus H1 /H2 blockade (2.8 ± 0.1 ml min(-1) mmHg(-1) ; P < 0.05), which did not differ from one another (P = 0.9). Given that ascorbate may catalyse the degradation of histamine in vivo, we conducted a follow-up study, in which subjects performed exercise in two conditions: (i) control; and (ii) i.v. N-acetylcysteine infusion. Postexercise vascular conductance was similar for control (4.0 ± 0.1 ml min(-1) mmHg(-1) ) and N-acetylcysteine conditions (4.0 ± 0.1 ml min(-1) mmHg(-1) ; P = 0.8). Thus, the results in the initial study were due to the degradation of histamine in skeletal muscle by ascorbate, because the histaminergic vasodilatation was unaffected by N-acetylcysteine. Overall, exercise-induced oxidative stress does not appear to contribute to sustained postexercise vasodilatation.
Asunto(s)
Ejercicio Físico/fisiología , Músculo Esquelético/fisiología , Resistencia Física/fisiología , Receptores Histamínicos H1/metabolismo , Receptores Histamínicos H2/metabolismo , Vasodilatación/fisiología , Antioxidantes/administración & dosificación , Ácido Ascórbico/administración & dosificación , Femenino , Agonistas de los Receptores Histamínicos/administración & dosificación , Humanos , Masculino , Músculo Esquelético/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Resistencia Física/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiología , Vasodilatación/efectos de los fármacos , Adulto JovenRESUMEN
Adolescence is a transitional phase marked by a heightened vulnerability to substances of abuse. It has been hypothesized that both increased sensitivity to reward and decreased sensitivity to aversive events may drive drug-use liability during this phase. To investigate possible age-related differences in sensitivity to the aversive consequences of drug use, adolescent and adult rats were compared on self-administration of cocaine before, during, and after a 10-day period in which an aversive agent, histamine, was added to the cocaine solution. Adult and adolescent female rats were trained to self-administer intravenous cocaine (0.4 mg/kg/infusion) over 10 sessions (2 h/session; 2 sessions/day). Histamine (4 mg/kg/infusion) was then added directly into the cocaine solution for the next 10 sessions. Finally, the cocaine/histamine solution was replaced with a cocaine-only solution, and rats continued to self-administer cocaine (0.4 mg/kg) for 20 sessions. Compared with adolescent rats, adult rats showed a greater decrease in cocaine self-administration when it was punished with intravenous histamine compared with their baseline cocaine self-administration rates. These results suggest that differences in the sensitivity to negative consequences of drug use may partially explain developmental differences in drug use vulnerability.
Asunto(s)
Cocaína/administración & dosificación , Inhibidores de Captación de Dopamina/administración & dosificación , Comportamiento de Búsqueda de Drogas/efectos de los fármacos , Comportamiento de Búsqueda de Drogas/fisiología , Agonistas de los Receptores Histamínicos/administración & dosificación , Histamina/administración & dosificación , Administración Intravenosa , Envejecimiento , Animales , Animales no Consanguíneos , Trastornos Relacionados con Cocaína/tratamiento farmacológico , Trastornos Relacionados con Cocaína/fisiopatología , Condicionamiento Operante/efectos de los fármacos , Femenino , Modelos Animales , Castigo , Ratas Wistar , AutoadministraciónRESUMEN
We aimed to investigate the effect of histamine on ciliary beat frequency (CBF) through combining high-speed digital microscopy and patch-clamp technology. Ciliated cells were obtained from septum and turbinate of 90-120-day-old healthy male guinea pigs. Tight seal was formed by applying negative pressure on the glass electrode after the drawing and pushing progress. Then, we enrolled high-speed digital microscopy to measure CBF before and after treatment with histamine of different concentrations ranging from 10(-6) to 10(-1) mol/L in Hank's solution and D-Hank's solution as well as after administrating adenosine triphosphate. One-way ANOVA, Student's t test or Kruskal-Wallis test was used for statistical comparisons. Glass electrode fix up ciliated cell is available at tip diameter of 2-5 µm and negative pressure of 10-20 cmH2O column. The baseline CBF in Hank's solution was higher than in D-Hank's solution. Treatment with 10(-6)-l0(-3) mol/L histamine of concentrations can stimulate a rise of CBF. Nevertheless, CBF in all groups decreased to baseline CBF within 20 min. Generally, 10(-2) mol/L histamine can stimulate a rise of CBF; meanwhile, the high concentration of histamine killed 50% ciliated cell. Histamine at 10(-1) mol/L killed all ciliated cells. Ciliary beating activity decreased in Ca(2+)-free solution. Moreover, adenosine triphosphate could increase CBF effectively after the stimulation effect of histamine. We construct an effective technology integrating patch-clamp technique with CBF measurements on ciliated cells. Extracellular histamine stimulation could increase CBF effectively.
Asunto(s)
Cilios/efectos de los fármacos , Histamina/administración & dosificación , Mucosa Nasal/efectos de los fármacos , Animales , Cilios/fisiología , Cobayas , Agonistas de los Receptores Histamínicos/administración & dosificación , Masculino , Mucosa Nasal/citología , Técnicas de Placa-Clamp , SolucionesAsunto(s)
Antipsicóticos/efectos adversos , Betahistina/administración & dosificación , Cognición/efectos de los fármacos , Agonistas de los Receptores Histamínicos/administración & dosificación , Esquizofrenia/tratamiento farmacológico , Pérdida de Peso/efectos de los fármacos , Adolescente , Edad de Inicio , Antipsicóticos/administración & dosificación , Quimioterapia Combinada/métodos , Humanos , Masculino , Olanzapina/administración & dosificación , Olanzapina/efectos adversos , Aumento de Peso/efectos de los fármacosRESUMEN
The basal forebrain (BF) is a key structure in regulating both cortical activity and sleep homeostasis. It receives input from all ascending arousal systems and is particularly highly innervated by histaminergic neurons. Previous studies clearly point to a role for histamine as a wake-promoting substance in the BF. We used in vivo microdialysis and pharmacological treatments in rats to study which electroencephalogram (EEG) spectral properties are associated with histamine-induced wakefulness and whether this wakefulness is followed by increased sleep and increased EEG delta power during sleep. We also investigated which BF neurons mediate histamine-induced cortical activation. Extracellular BF histamine levels rose immediately and remained constant throughout a 6 h period of sleep deprivation, returning to baseline levels immediately afterward. During the spontaneous sleep-wake cycle, we observed a strong correlation between wakefulness and extracellular histamine concentrations in the BF, which was unaffected by the time of day. The perfusion of histamine into the BF increased wakefulness and cortical activity without inducing recovery sleep. The perfusion of a histamine receptor 1 antagonist into the BF decreased both wakefulness and cortical activity. Lesioning the BF cholinergic neurons abolished these effects. Together, these results show that activation of the cholinergic BF by histamine is important in sustaining a high level of cortical activation, and that a lack of activation of the cholinergic BF by histamine may be important in initiating and maintaining nonrapid eye movement sleep. The level of histamine release is tightly connected to behavioral state, but conveys no information about sleep pressure.
Asunto(s)
Corteza Cerebral/fisiología , Neuronas Colinérgicas/fisiología , Liberación de Histamina/fisiología , Prosencéfalo/citología , Prosencéfalo/metabolismo , Análisis de Varianza , Animales , Anticuerpos Monoclonales/toxicidad , Corteza Cerebral/efectos de los fármacos , Colina O-Acetiltransferasa/metabolismo , Colinérgicos/toxicidad , Neuronas Colinérgicas/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Electroencefalografía , Electromiografía , Análisis de Fourier , Lateralidad Funcional , Histamina/administración & dosificación , Agonistas de los Receptores Histamínicos/administración & dosificación , Antagonistas de los Receptores Histamínicos/farmacología , Liberación de Histamina/efectos de los fármacos , Masculino , Microdiálisis , Prosencéfalo/efectos de los fármacos , Prosencéfalo/lesiones , Ratas , Ratas Wistar , Proteínas Inactivadoras de Ribosomas Tipo 1/toxicidad , Saporinas , Privación de Sueño/fisiopatología , Fases del Sueño/efectos de los fármacos , Fases del Sueño/fisiología , Factores de Tiempo , Vigilia/efectos de los fármacosRESUMEN
The role of the nucleus basalis magnocellularis (NBM) in fear conditioning encoding is well established. In the present report, we investigate the involvement of the NBM histaminergic system in consolidating fear memories. The NBM was injected bilaterally with ligands of histaminergic receptors immediately after contextual fear conditioning. Histaminergic compounds, either alone or in combination, were stereotaxically administered to different groups of adult male Wistar rats and memory was assessed as conditioned freezing duration 72 h after administration. This protocol prevents interference with NBM function during either acquisition or retrieval phases, hence restricting the effect of pharmacological manipulations to fear memory consolidation. The results presented here demonstrate that post-training H3 receptors (H3R) blockade with the antagonist/inverse agonist thioperamide or activation with immepip in the NBM potentiates or decreases, respectively, freezing response at retrieval. Thioperamide induced memory enhancement seems to depend on H2R, but not H1R activation, as the H2R antagonist zolantidine blocked the effect of thioperamide, whereas the H1R antagonist pyrilamine was ineffective. Furthermore, the H2R agonist ampthamine improved fear memory expression independently of the H3R agonist effect. Our results indicate that activation of post-synaptic H2R within the NBM by endogenous histamine is responsible for the potentiated expression of fear responses. The results are discussed in terms of activation of H3 auto- and heteroreceptors within the NBM and the differential effect of H3R ligands on fear memory consolidation in distinct brain regions.
Asunto(s)
Núcleo Basal de Meynert/metabolismo , Condicionamiento Psicológico/fisiología , Miedo/fisiología , Agonistas de los Receptores Histamínicos/metabolismo , Antagonistas de los Receptores Histamínicos/metabolismo , Receptores Histamínicos H3/metabolismo , Animales , Núcleo Basal de Meynert/efectos de los fármacos , Condicionamiento Psicológico/efectos de los fármacos , Miedo/efectos de los fármacos , Agonistas de los Receptores Histamínicos/administración & dosificación , Antagonistas de los Receptores Histamínicos/administración & dosificación , Inyecciones Intraventriculares , Ligandos , Masculino , Ratas , Ratas WistarRESUMEN
The aim of the study is to evaluate the effectiveness of ozone and betahistine treatments in the treatment of tinnitus. Sixty-eight patients were enrolled in this randomized, prospective controlled study. The ozone group consisted of 27, betahistine group consisted of 26 and control group consisted of 15 patients. The patients in ozone group received 10 sessions of ozone treatment via major autohemotherapy. Betahistine group received 48 mg/day betahistine tablets per oral for 3 months duration. The control group was followed up without any treatment given. The evaluation of tinnitus was made by tinnitus loudness and tinnitus handicap inventory (THI). The changes in findings from baseline to 3rd and 6th months were assessed, and the group results were compared. Comparison of the initial mean tinnitus loudness and 3 and 6 months after treatment in each of the three groups did not reveal a significant difference. The comparison between the groups in terms of the improvement of tinnitus loudness was not significant (p = 0.821). Comparison of the initial mean THI and 3 and 6 months after treatment revealed a significant difference in ozone and betahistine groups but not in the control group. When the delta (Δ) THI (the change of mean THI between the initial and 6th month) was compared between the groups, there was no significant difference. This randomized controlled study investigating the effects of ozone in tinnitus tries to shed light to a new method of treatment in tinnitus. The findings of the study does not provide enough evidence to support ozone and betahistine as a treatment for tinnitus and further research on the subject is necessary.
Asunto(s)
Betahistina/administración & dosificación , Agonistas de los Receptores Histamínicos/administración & dosificación , Ozono/administración & dosificación , Acúfeno/terapia , Adulto , Anciano , Análisis de Varianza , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Índice de Severidad de la EnfermedadRESUMEN
RATIONALE: Skin responses to standardized positive and negative controls are important in the interpretation of a skin prick tests (SPT). However, this information in young children is lacking. We aimed to determine skin reactivity and compare the skin responses to these controls on the upper back and forearm in young children. METHODS: SPTs for histamine hydrochloride 1 mg/ml (positive control) and 50% glycerol-saline (negative control) were performed on the upper back and forearm of children aged 6-25 months who came to the well-child clinic at Songklanagarind Hospital. SPTs to common allergens (cow's milk, soybean, egg white and house dust mite) were also evaluated. RESULTS: A total of 133 children with a mean age of 12.4 months were enrolled in the study. Seventy-five children (56.4%) were male. The results from the upper back and the forearm of the histamine-induced mean wheal diameter + standard deviation (SD) were 4.74+1.37 mm and 3.86+1.82mm (p < 0.0001). The mean flare responses to histamine on the upper back and the forearm were 18.47 +/- 4.28 mm and 16.37 +/- 5.50 mm (p < 0.0001). The SPT results from the negative control on the upper back and forearm also had significant differences among the sizes of the wheal (0.57+1.17 vs. 0.34+0.89 mm, p = 0.007) and flare (4.57 +/- 3.04 mm vs. 3.34 +/- 1.91 mm, p < 0.0001). CONCLUSIONS: Our study showed regional differences in wheal and flare responses to standardized positive and negative controls in young children. The upper back is more reactive than the forearm and is the preferred SPT site in young-aged children.
Asunto(s)
Dorso , Antebrazo , Agonistas de los Receptores Histamínicos/administración & dosificación , Histamina/administración & dosificación , Hipersensibilidad/inmunología , Piel/inmunología , Preescolar , Femenino , Histamina/inmunología , Agonistas de los Receptores Histamínicos/inmunología , Humanos , Hipersensibilidad/diagnóstico , Lactante , Masculino , Pruebas Cutáneas/métodosRESUMEN
To avoid serious causes of dizziness and establishing preliminary diagnosis is usually enough sighting history taking and physical examination of the patient. Great importance is self-presenting patients with complaints of dizziness. In recent years, for treatment of various types vestybulopatiy, but also for the prevention of attacks, successfully used betahistyn hydrochloride, which improves the quality of care and well-being of the patient.
Asunto(s)
Mareo/diagnóstico , Vértigo/diagnóstico , Neuronitis Vestibular/diagnóstico , Adulto , Betahistina/administración & dosificación , Betahistina/uso terapéutico , Diagnóstico Diferencial , Mareo/tratamiento farmacológico , Mareo/etiología , Femenino , Agonistas de los Receptores Histamínicos/administración & dosificación , Agonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Masculino , Resultado del Tratamiento , Vértigo/tratamiento farmacológico , Vértigo/etiología , Neuronitis Vestibular/tratamiento farmacológico , Neuronitis Vestibular/etiología , Adulto JovenRESUMEN
Axons of histamine (HA)-containing neurons are known to project from the posterior hypothalamus to many areas of the brain, including the nucleus tractus solitarii (NTS), a central brain structure that plays an important role in regulating arterial pressure. However, the functional significance of NTS HA is still not fully established. In this study, we microinjected HA or 2-pyridylethylamine, a HA-receptor H(1)-specific agonist, into the NTS of urethane-anesthetized Wister rats to identify the potential functions of NTS HA on cardiovascular regulation. When HA or H(1)-receptor-specific agonist was bilaterally microinjected into the NTS, mean arterial pressure (MAP) and heart rate (HR) were significantly increased, whereas pretreatment with the H(1)-receptor-specific antagonist cetirizine into the NTS significantly inhibited the cardiovascular responses. The maximal responses of MAP and HR changes induced by HA or H(1)-receptor-specific agonist were dose dependent. We also confirmed gene expression of HA receptors in the NTS and that the expression level of H(1) mRNA was higher than that of the other subtypes. In addition, we found that H(1) receptors are mainly expressed in neurons of the NTS. These findings suggested that HA within the NTS may play a role in regulating cardiovascular homeostasis via activation of H(1) receptors expressed in the NTS neurons.
Asunto(s)
Presión Sanguínea , Frecuencia Cardíaca , Histamina/metabolismo , Receptores Histamínicos H1/metabolismo , Núcleo Solitario/metabolismo , Análisis de Varianza , Animales , Presión Sanguínea/efectos de los fármacos , Cetirizina/administración & dosificación , Relación Dosis-Respuesta a Droga , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Frecuencia Cardíaca/efectos de los fármacos , Histamina/administración & dosificación , Agonistas de los Receptores Histamínicos/administración & dosificación , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Inmunohistoquímica , Masculino , Microinyecciones , Piridinas/administración & dosificación , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Receptores Histamínicos H1/efectos de los fármacos , Receptores Histamínicos H1/genética , Núcleo Solitario/efectos de los fármacosRESUMEN
Non-reinforced retrieval induces memory extinction, a phenomenon characterized by a decrease in the intensity of the learned response. This attribute has been used to develop extinction-based therapies to treat anxiety and post-traumatic stress disorders. Histamine modulates memory and anxiety but its role on fear extinction has not yet been evaluated. Therefore, using male Wistar rats, we determined the effect of the intra-hippocampal administration of different histaminergic agents on the extinction of step-down inhibitory avoidance (IA), a form of aversive learning. We found that intra-CA1 infusion of histamine immediately after non-reinforced retrieval facilitated consolidation of IA extinction in a dose-dependent manner. This facilitation was mimicked by the histamine N-methyltransferase inhibitor SKF91488 and the H2 receptor agonist dimaprit, reversed by the H2 receptor antagonist ranitidine, and unaffected by the H1 antagonist pyrilamine, the H3 antagonist thioperamide and the antagonist at the NMDA receptor (NMDAR) polyamine-binding site ifenprodil. Neither the H1 agonist 2-2-pyridylethylamine nor the NMDAR polyamine-binding site agonist spermidine affected the consolidation of extinction while the H3 receptor agonist imetit hampered it. Extinction induced the phosphorylation of ERK1 in dorsal CA1 while intra-CA1 infusion of the MEK inhibitor U0126 blocked extinction of the avoidance response. The extinction-induced phosphorylation of ERK1 was enhanced by histamine and dimaprit and blocked by ranitidine administered to dorsal CA1 after non-reinforced retrieval. Taken together, our data indicate that the hippocampal histaminergic system modulates the consolidation of fear extinction through a mechanism involving the H2-dependent activation of ERK signalling.
Asunto(s)
Miedo , Histamina/fisiología , Proteínas del Tejido Nervioso/fisiología , Inhibición Neural , Neuronas/metabolismo , Receptores Histamínicos H2/fisiología , Transducción de Señal , Animales , Conducta Animal/efectos de los fármacos , Región CA1 Hipocampal/efectos de los fármacos , Región CA1 Hipocampal/metabolismo , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacología , Miedo/efectos de los fármacos , Histamina/administración & dosificación , Agonistas de los Receptores Histamínicos/administración & dosificación , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores H2 de la Histamina/administración & dosificación , Antagonistas de los Receptores H2 de la Histamina/farmacología , Histamina N-Metiltransferasa/antagonistas & inhibidores , Infusiones Intraventriculares , Masculino , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Proteínas del Tejido Nervioso/agonistas , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Inhibición Neural/efectos de los fármacos , Neuronas/efectos de los fármacos , Fosforilación/efectos de los fármacos , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Ratas , Ratas Wistar , Receptores Histamínicos H2/química , Receptores Histamínicos H3/química , Receptores Histamínicos H3/fisiología , Transducción de Señal/efectos de los fármacosRESUMEN
BACKGROUND: Anecdotal evidence suggests that 'contagious' itch occurs in daily life when we see other people itch and scratch. This phenomenon has not previously been studied systematically, and factors which can amplify itch perception were unknown. OBJECTIVES: We investigated whether exposure to visual cues of itch can induce or intensify itch in healthy subjects and patients with atopic dermatitis (AD). METHODS: Participants received histamine or a saline control delivered to the forearm and were asked to watch short video clips of people scratching. Spontaneous scratching induced by visual cues was monitored and analysed. RESULTS: Patients with AD reported a higher itch intensity and scratched more frequently while watching itch videos, even in the presence of mock itch stimuli. CONCLUSIONS: Human susceptibility to develop itch when exposed to visual cues is confirmed; it appears to be amplified in patients with AD. These findings suggest that interpersonal social cues can dramatically alter the subjective sensory experience of itch.
Asunto(s)
Señales (Psicología) , Dermatitis Atópica/psicología , Prurito/psicología , Adolescente , Adulto , Femenino , Histamina/administración & dosificación , Histamina/farmacología , Agonistas de los Receptores Histamínicos/administración & dosificación , Agonistas de los Receptores Histamínicos/farmacología , Humanos , Masculino , Persona de Mediana Edad , Percepción , Estimulación Luminosa/métodos , Grabación de Cinta de Video , Adulto JovenRESUMEN
It is important to search for a promising therapeutic target or small molecules that can control excessive eating since limiting the intake of foods, especially tasty ones, could be effective in the treatment or prevention of obesity. Some studies indicate betahistine as an unique drug having the ability to ameliorate, for example, antipsychotic-induced weight gain. This study aimed to determine whether repeated administration of betahistine (histamine H1R agonist and H3R antagonist) could be beneficial in reducing the intake of tasty foods or the body's response to overeating via mechanisms such as by influencing the levels of hormones involved in the regulation of food intake or the levels of selected metabolic parameters. Studies were performed in the excessive eating model in rats, which perfectly illustrates the harmful high-caloric intake from freely available tasty products rich in sugar and fat. Our results indicated that repeated administration of betahistine to rats caused lower gain of body mass compared to the control rats fed palatable feed. Interestingly, betahistine treatment increased the consumption of cheese, which is a source of histamine. Although betahistine did not prevent the development of metabolic disorders, such as reduced glucose tolerance, in test animals, it significantly increased the level of high-density lipoprotein cholesterol, which could certainly be considered beneficial. Further studies should be conducted to investigate the effect of repeated administration of betahistine on satiety, gastrointestinal disorders, and the preference for histamine-containing foods.